HFM
ABUS icon

Hartford Financial Management’s Arbutus Biopharma ABUS Stock Holding History

Hartford Financial Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.32K Hold
900
– – ﹤0.01% 308
2026
Q1 		$4.05K Hold
900
– – ﹤0.01% 306
2025
Q4 		$4.33K Hold
900
– – ﹤0.01% 301
2025
Q3 		$4.09K Hold
900
– – ﹤0.01% 303
2025
Q2 		$2.78K Hold
900
– – ﹤0.01% 310
2025
Q1 		$3.14K Hold
900
– – ﹤0.01% 318
2024
Q4 		$2.94K Hold
900
– – ﹤0.01% 339
2024
Q3 		$3.46K Hold
900
– – ﹤0.01% 340
2024
Q2 		$2.78K Buy
+900
New +$2.7K ﹤0.01% 346

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Hartford Financial Management's ABUS Position: Q2 2026 in Review

Hartford Financial Management held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 900 shares worth $4.32K. The position accounts for ﹤0.01% of the portfolio, ranked #308.

Hartford Financial Management first reported a position in ABUS in Q2 2024 and has held it in 9 quarters since. The position peaked at $4.33K in Q4 2025. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Hartford Financial Management held 900 shares of Arbutus Biopharma worth $4.32K as of Q2 2026.
  • Hartford Financial Management left its Arbutus Biopharma share count unchanged in Q2 2026.
  • Arbutus Biopharma made up ﹤0.01% of Hartford Financial Management's portfolio in Q2 2026, its #308 holding.
  • Hartford Financial Management first reported a position in Arbutus Biopharma in Q2 2024 and has held it in 9 quarters since.
  • Hartford Financial Management's Arbutus Biopharma position peaked at $4.33K in Q4 2025.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Hartford Financial Management's 13F filing for Q2 2026, filed 24 Jul 2026.